Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease

Completed · Phase 1/Phase 2

Conditions studied: Huntington's Disease

In brief

This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington's disease, including cognitive (thinking abilities), motor (movement), behavior, and overall functioning.

Key facts

Study ID

NCT00387270

Run by

Medivation, Inc.

People needed

9

Starts

2006-10-01

Expected to finish

2007-03-01

Last updated by the study team

2008-01-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical features of Huntington's disease and a confirmatory family history of HD, or a CAG repeat expansion greater than or equal to 36
• Stage I,II,III HD and a total functional capacity greater than or equal to 5 on the Unified Huntington's Disease Rating Scale

You may not qualify if…

• Clinical evidence of unstable medical illness

Where it is running

• Huntington Study Group — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.